サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：気道可逆性疾患治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415691

気道可逆性疾患治療の世界市場レポート 2024年

Reversible Airway Diseases Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
気道可逆性疾患治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

気道可逆性疾患治療市場規模は近年力強く成長しています。2023年の794億3,000万米ドルから2024年には855億3,000万米ドルへ、CAGR7.7％で成長します。実績期間の成長は、気道可逆性疾患の有病率の上昇、気道可逆性疾患に対する意識の高まり、ヘルスケアへのアクセスの増加、可処分所得の上昇に起因しています。

気道可逆性疾患治療市場規模は、今後数年間で力強い成長が見込まれます。2028年には年間平均成長率（CAGR）6.6％で1,102億8,000万米ドルに成長します。予測期間の成長は、人口の高齢化、慢性疾患の有病率の増加、都市化と大気汚染の増加、ヘルスケアへのアクセスの拡大に起因しています。予測期間の主な動向には、デジタルヘルス技術、新しい治療法の研究開発、早期介入と予防、吸入器技術の進歩などがあります。

慢性呼吸器疾患の有病率の増加は、予測可能な将来において、気道可逆性疾患治療市場の拡大の重要な促進要因になると考えられています。慢性呼吸器疾患には、肺、気管支、気管、喉頭、咽頭、鼻腔からなる呼吸器系に影響を及ぼすさまざまな病状が含まれます。慢性呼吸器疾患の検査と治療は、特に急性呼吸窮迫症候群のような状態の早期発見と診断において極めて重要な役割を果たします。タイムリーな介入と効果的な管理は、合併症のリスクとこれらの疾患の進行を軽減します。例えば、2021年2月現在、スイスを拠点とする市民団体NCDアライアンスのデータによると、肺がんは世界規模でがん関連死の主な原因となっており、220万人の新規患者と180万人の死亡者を占めています。さらに、Lancet誌が2022年9月に発表したデータによると、2021年に新たに発生した呼吸器合胞体ウイルスの症例数は11,255例で、2020年に報告された9,972例から11.4％増加しています。したがって、慢性呼吸器疾患の罹患率の上昇は、気道可逆性疾患治療市場の成長を促進すると予測されます。

ヘルスケア支出の増加は、気道可逆性疾患治療市場の今後数年間の成長の主要な促進要因になると予測されます。ヘルスケア支出は、特定のヘルスケアシステムや経済圏において、一定期間にヘルスケアサービスや関連活動に割り当てられる総財源を包含します。医療支出の増加傾向は、研究開発、患者教育、先進医薬品へのアクセス、最先端技術の開発への投資の増加を促進するため、気道可逆性疾患の治療という文脈では特に重要です。その結果、ヘルスケア支出の増加は、気道可逆性疾患に罹患した患者の管理と治療成績の向上に寄与します。例えば、2022年11月現在、カナダを拠点とする保健機関であるカナダ保健情報研究所（CIHI）の報告書によると、カナダの医療費は2021年に3,280億米ドルに達し、その後2022年には3,310億米ドルに増加しました。このように、医療費の高騰が気道可逆性疾患治療市場の拡大を後押ししています。

2023年の気道可逆性疾患治療市場では北米が最大地域でした。アジア太平洋は予測期間中に最も急成長する地域と予想されます。気道可逆性疾患治療レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の気道可逆性疾患治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 胸部X線
  • コンピュータ断層撮影（CT）スキャン
  • 肺療法
  • 外科的移植
  • 薬剤
  • 世界の気道可逆性疾患治療市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 喘息
  • 慢性気管支炎
  • 肺気腫
  • 嚢胞性線維症
  • 細気管支炎
  • その他
  • 世界の気道可逆性疾患治療市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他

第7章 地域および国の分析

  • 世界の気道可逆性疾患治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の気道可逆性疾患治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 気道可逆性疾患治療市場の競合情勢
  • 気道可逆性疾患治療市場の企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Sanofi S.A.
  • GlaxoSmithKline Plc
  • Medtronic plc
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Grifols SA
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Dragerwerk AG & Co. KGaA
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12290

“Reversible Airway Diseases Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on reversible airway diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for reversible airway diseases treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The reversible airway diseases treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment : Chest X Ray; Computed Tomography (CT) Scan; Lung Therapies; Surgery Transplant; Medications
  • 2) By Diseases: Asthma; Chronic Bronchitis; Emphysema; Cystic Fibrosis; Bronchiolitis; Other Diseases
  • 3) By End-Users: Hospitals; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Reversible airway diseases refer to conditions characterized by the temporary narrowing of airways, typically caused by inflammation and constriction of the surrounding smooth muscles. The primary objective of treating these conditions is to alleviate symptoms like cough and shortness of breath in order to enhance lung function.

The main categories of treatment options for reversible airway diseases include diagnostic procedures such as chest X-rays and computed tomography (CT) scans, therapeutic lung interventions, surgical procedures, organ transplants, and medications. A chest X-ray is a diagnostic imaging method that employs a small amount of ionizing radiation to produce images of the chest's internal structures, encompassing the heart, lungs, and bones. Various reversible airway diseases include asthma, chronic bronchitis, emphysema, cystic fibrosis, bronchiolitis, and others. These treatment approaches are utilized by diverse end-users, including hospitals, specialty clinics, and other healthcare facilities.

The reversible airway diseases treatment market research report is one of a series of new reports from The Business Research Company that provides reversible airway diseases treatment market statistics, including reversible airway diseases treatment industry global market size, regional shares, competitors with a reversible airway diseases treatment market share, detailed reversible airway diseases treatment market segments, market trends and opportunities and any further data you may need to thrive in the reversible airway diseases treatment industry. This reversible airway diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The reversible airway diseases treatment market size has grown strongly in recent years. It will grow from $79.43 billion in 2023 to $85.53 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to rising prevalence of reversible airway diseases, growing awareness of reversible airway diseases, increasing access to healthcare, rising disposable incomes.

The reversible airway diseases treatment market size is expected to see strong growth in the next few years. It will grow to $110.28 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to aging population, increasing prevalence of chronic diseases, rising urbanization and air pollution, expanding access to healthcare. Major trends in the forecast period include digital health technologies, research and development of new treatments, early intervention and prevention, inhaler technology advancements.

The increasing prevalence of chronic respiratory diseases is poised to be a significant driver of the reversible airway disease treatment market's expansion in the foreseeable future. Chronic respiratory diseases encompass a range of medical conditions affecting the respiratory system, comprising the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. The testing and treatment of chronic respiratory diseases play a pivotal role in early detection and diagnosis, particularly for conditions like acute respiratory distress syndrome. Timely intervention and effective management reduce the risk of complications and the progression of these diseases. For example, as of February 2021, data from the NCD Alliance, a Switzerland-based civil society organization, reveals that lung cancer stands as the primary cause of cancer-related deaths on a global scale, accounting for 2.2 million new cases and 1.8 million fatalities. Furthermore, the data published by The Lancet in September 2022 indicates that there were 11,255 new cases of respiratory syncytial virus in 2021, marking an 11.4% increase from the 9,972 cases reported in 2020. Hence, the escalating incidence of chronic respiratory diseases is anticipated to drive the growth of the reversible airway disease treatment market.

The growing healthcare expenditure is poised to be a key driver of the reversible airway disease treatment market's growth in the coming years. Healthcare expenditure encompasses the total financial resources allocated to healthcare services and associated activities within a specific healthcare system or economy over a defined period. The upward trend in healthcare spending is particularly significant in the context of treating reversible airway diseases, as it facilitates increased investments in research and development, patient education, access to advanced medications, and the development of cutting-edge technologies. Consequently, higher healthcare expenditures contribute to enhancing the management and treatment outcomes for individuals affected by reversible airway diseases. For example, as of November 2022, according to a report by the Canadian Institute for Health Information (CIHI), a Canada-based health organization, Canada's healthcare expenditure reached $328 billion in 2021 and subsequently increased to $331 billion in 2022. Thus, the escalating healthcare expenditures are propelling the expansion of the reversible airway disease treatment market.

The restricted availability of vital inhaled therapies for individuals with COPD in low and middle-income countries (LMICs) is posing a hurdle to the growth of the reversible airway disease treatment market. Inhalation therapy is a medical approach that enables the direct delivery of medications into the airways via inhalation devices. However, in LMICs, there is a lack of access to and affordability of crucial inhaled therapies for individuals with COPD, which can limit their ability to receive effective treatment options. For example, as of October 2022, data from the Lancet Global Health indicated that only six out of 58 countries achieved the 80% availability target for short-acting beta-agonists (SABAs), and merely three out of 48 met the minimum requirement for inhaled corticosteroids (ICSs). Consequently, the inadequate accessibility of essential inhaled therapies for COPD patients in low- and middle-income countries (LMICs) is impeding the advancement of the reversible airway disease treatment market.

The prominent companies within the reversible airway disease treatment market are placing a significant emphasis on inhalation-based dosage forms for respiratory drug delivery to maintain their market presence. For instance, in June 2021, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Tiogiva, a Tiotropium Bromide Dry Powder Inhaler (DPI) in the United Kingdom. Tiogiva is a bioequivalent alternative to Boehringer Ingelheim's Spiriva Handihaler, designed for managing chronic obstructive pulmonary disease (COPD). COPD is a chronic condition characterized by lung inflammation, damage to lung tissue, and airway constriction. Glenmark Pharmaceuticals has plans to expand the product's availability throughout Western Europe, introducing it under various brand names such as Tiogiva in Ireland, Sweden, Finland, and Norway; Tavulus in Denmark, Spain, and the Netherlands; and Tiotropium Glenmark in Germany.

In October 2022, Lupin Ltd., an India-based pharmaceutical company, completed the purchase of two inhalation product brands from Sunovion Pharmaceuticals Inc. for $75 million. This strategic acquisition is set to fortify Lupin Ltd.'s inhalation product portfolio, with the addition of two brands, including Brovana (arformoterol tartrate) inhalation solution. Brovana is specifically indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including those with reversible obstructive airway disease. The move serves to enhance Lupin Ltd.'s presence in the field of respiratory therapy. Sunovion Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in the treatment of reversible airway diseases.

Major players in the reversible airway diseases treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline Plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Grifols SA, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Dragerwerk AG & Co. KGaA, Dr. Reddy's Laboratories Ltd., Cipla Limited, Getinge AB, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Fisher & Paykel Healthcare Corporation Limited .

North America was the largest region in the reversible airway diseases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reversible airway disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the reversible airway disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The reversible airway disease treatment market consists of sales of biological therapies and oxygen therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The reversible airway disease treatment market also includes sales of anti-inflammatory drugs, monoclonal antibody drugs and medical devices such as inhaler devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Reversible Airway Diseases Treatment Market Characteristics

3. Reversible Airway Diseases Treatment Market Trends And Strategies

4. Reversible Airway Diseases Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Reversible Airway Diseases Treatment Market Size and Growth

  • 5.1. Global Reversible Airway Diseases Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Reversible Airway Diseases Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Reversible Airway Diseases Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Reversible Airway Diseases Treatment Market Segmentation

  • 6.1. Global Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Chest X Ray
  • Computed Tomography (CT) Scan
  • Lung Therapies
  • Surgery Transplant
  • Medications
  • 6.2. Global Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Asthma
  • Chronic Bronchitis
  • Emphysema
  • Cystic Fibrosis
  • Bronchiolitis
  • Other Diseases
  • 6.3. Global Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Other End-Users

7. Reversible Airway Diseases Treatment Market Regional And Country Analysis

  • 7.1. Global Reversible Airway Diseases Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Reversible Airway Diseases Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Reversible Airway Diseases Treatment Market

  • 8.1. Asia-Pacific Reversible Airway Diseases Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Reversible Airway Diseases Treatment Market

  • 9.1. China Reversible Airway Diseases Treatment Market Overview
  • 9.2. China Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Reversible Airway Diseases Treatment Market

  • 10.1. India Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Reversible Airway Diseases Treatment Market

  • 11.1. Japan Reversible Airway Diseases Treatment Market Overview
  • 11.2. Japan Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Reversible Airway Diseases Treatment Market

  • 12.1. Australia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Reversible Airway Diseases Treatment Market

  • 13.1. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Reversible Airway Diseases Treatment Market

  • 14.1. South Korea Reversible Airway Diseases Treatment Market Overview
  • 14.2. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Reversible Airway Diseases Treatment Market

  • 15.1. Western Europe Reversible Airway Diseases Treatment Market Overview
  • 15.2. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Reversible Airway Diseases Treatment Market

  • 16.1. UK Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Reversible Airway Diseases Treatment Market

  • 17.1. Germany Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Reversible Airway Diseases Treatment Market

  • 18.1. France Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Reversible Airway Diseases Treatment Market

  • 19.1. Italy Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Reversible Airway Diseases Treatment Market

  • 20.1. Spain Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Reversible Airway Diseases Treatment Market

  • 21.1. Eastern Europe Reversible Airway Diseases Treatment Market Overview
  • 21.2. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Reversible Airway Diseases Treatment Market

  • 22.1. Russia Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Reversible Airway Diseases Treatment Market

  • 23.1. North America Reversible Airway Diseases Treatment Market Overview
  • 23.2. North America Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Reversible Airway Diseases Treatment Market

  • 24.1. USA Reversible Airway Diseases Treatment Market Overview
  • 24.2. USA Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Reversible Airway Diseases Treatment Market

  • 25.1. Canada Reversible Airway Diseases Treatment Market Overview
  • 25.2. Canada Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Reversible Airway Diseases Treatment Market

  • 26.1. South America Reversible Airway Diseases Treatment Market Overview
  • 26.2. South America Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Reversible Airway Diseases Treatment Market

  • 27.1. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Reversible Airway Diseases Treatment Market

  • 28.1. Middle East Reversible Airway Diseases Treatment Market Overview
  • 28.2. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Reversible Airway Diseases Treatment Market

  • 29.1. Africa Reversible Airway Diseases Treatment Market Overview
  • 29.2. Africa Reversible Airway Diseases Treatment Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Reversible Airway Diseases Treatment Market, Segmentation By Diseases, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Reversible Airway Diseases Treatment Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Reversible Airway Diseases Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Reversible Airway Diseases Treatment Market Competitive Landscape
  • 30.2. Reversible Airway Diseases Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Reversible Airway Diseases Treatment Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. GlaxoSmithKline Plc
  • 31.3. Medtronic plc
  • 31.4. Eli Lilly and Company
  • 31.5. Gilead Sciences Inc.
  • 31.6. Amgen Inc.
  • 31.7. Boehringer Ingelheim International GmbH
  • 31.8. Viatris Inc.
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Grifols SA
  • 31.11. Sumitomo Dainippon Pharma Co. Ltd.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Dragerwerk AG & Co. KGaA
  • 31.14. Dr. Reddy's Laboratories Ltd.
  • 31.15. Cipla Limited

32. Global Reversible Airway Diseases Treatment Market Competitive Benchmarking

33. Global Reversible Airway Diseases Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Reversible Airway Diseases Treatment Market

35. Reversible Airway Diseases Treatment Market Future Outlook and Potential Analysis

  • 35.1 Reversible Airway Diseases Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Reversible Airway Diseases Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Reversible Airway Diseases Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer